Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium‐Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes
Main finding · SGLT2i discontinuationResult — go to the resultHazard ratio 1.83 95% CI 1.79–1.87Authors' conclusion
Hospitalisation is a strong risk factor for discontinuation of SGLT2i and DPP-4i therapy.
Study context
- Population
- Adults aged ≥40 years in New South Wales, Australia, initiating SGLT2i or DPP-4i (separate cohorts) between 2016 and 2020; SGLT2i cohort median age 63 years, 61% maleSGLT2i initiators
- Participants
- 106,098 adults
- Exposure
- Hospitalisation period vs other follow-up times
- Outcome
- SGLT2i discontinuation (gap of ≥90 days without a dispensing of the index medicine)
- Follow-up
- Until death, mid-2021, or discontinuation
Methodological detailsnew-user cohort, population-level linked data, time-dependent exposure, Cox proportional hazards models, adjusted for demographic and clinical characteristics
- New-user cohort
- Population-level linked data
- Time-dependent exposure
- Cox proportional hazards models, adjusted for demographic and clinical characteristics
Main finding
SGLT2i discontinuation
Hazard ratio
1.83
95% CI 1.79–1.87
By group
Hospitalisation period
56.4 per 100 person-years
Other follow-up times
37.6 per 100 person-years
Hospitalisation periodvs Other follow-up times
HR 1.83 (95% CI 1.79–1.87)
As reported in the abstract
- Hospitalised during follow-up
- 35.1%
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium‐Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes. Diabetes Obes Metab. Published 17 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →